Atovaquone-Proguanil: A Promising Therapy for Persistent Relapsing Babesiosis

Area of Science:

• Infectious Diseases
• Immunology
• Oncology

Background:

• Babesiosis is a tick-borne illness caused by *Babesia* parasites.
• Immunocompromised hosts, particularly those with B-cell depletion (e.g., due to rituximab therapy for B-cell malignancies), are at high risk for severe and persistent babesiosis.
• Antibody production by B-cells is crucial for controlling *Babesia* infection.

Observation:

• This case study details a patient with persistent, relapsing babesiosis.
• The patient was immunocompromised due to treatment for a malignant B-cell disorder.
• Standard treatments may be less effective in immunocompromised individuals.

Findings:

• Successful management of persistent, relapsing babesiosis was achieved using atovaquone-proguanil (Malarone).
• Atovaquone-proguanil served as a salvage regimen, indicating its utility when other treatments fail or resistance occurs.
• Balancing the risks and benefits of continuing immunosuppressive cancer therapy versus reducing immunosuppression levels was critical.

Implications:

• Atovaquone-proguanil represents a valuable therapeutic option for refractory babesiosis in immunocompromised patients.
• Careful consideration of the patient's overall treatment plan, including immunosuppression management, is as vital as antimicrobial selection.
• This case highlights the complexity of treating opportunistic infections in immunocompromised populations and suggests a potential role for novel therapeutic combinations.